Key result
Inhibition of miR-34a reduced the severity of experimental cardiac fibrosis in a mouse model of myocardial infarction by directly targeting Smad4 expression.
Inhibition of miR-34a reduces post-myocardial infarction cardiac fibrosis by targeting Smad4, suggesting it may be a promising therapeutic target.
Hypothesis-generating for miR-34a inhibition in post-MI fibrosis; leaves open translation to human therapy.
BACKGROUND: Although few microRNAs (miRNAs) have been involved in the regulation of post-ischemic cardiac fibrosis, the exact effect and underlying mechanism of miRNAs in cardiac fibrosis remains unclear. Here, we sought to investigate whether microRNA-34 (miR-34) plays a role in the pathogenic development of myocardial fibrosis. METHODS: The myocardial infarction (MI) mice model was induced and cardiac fibroblasts were cultured. Histological analyses, quantitative real-time polymerase chain reaction and Western blotting analysis were used. RESULTS: We found that the miR-34 cluster, especially miR-34a, was upregulated in the MI heart. In vivo, inhibition of miR-34a reduces the severity of experimental cardiac fibrosis in mice. TGF-β1 increased miR-34a expression in cardiac fibroblasts. Overexpressing miR-34a levels increased the profibrogenic activity of TGF-β1 in cardiac fibroblast, whereas inhibition miR-34a levels weakened the activity. Finally, we showed that miR-34a's underlying mechanism during cardiac fibrosis occurs through the targeting of Smad4 expression. CONCLUSIONS: Our findings provide evidence that miR-34a plays a critical role in the progression of cardiac tissue fibrosis by directly targeting Smad4, which suggests that miR-34a may be new marker for cardiac fibrosis progression and that inhibition of miR-34a may be a promising strategy in the treatment of cardiac fibrosis.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2014) studied Myocardial infarction and cardiac fibrosis. Inhibition of miR-34a was evaluated on Severity of experimental cardiac fibrosis. Inhibition of miR-34a reduced the severity of experimental cardiac fibrosis in a mouse model of myocardial infarction by directly targeting Smad4 expression.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: